Atazanavir API

Atazanavir APIyog ib qho tshuaj tiv thaiv kab mob uas feem ntau siv los kho tus kab mob HIV. Nws belongs rau ib chav kawm ntawm cov tshuaj hu ua protease inhibitors, uas ua haujlwm los ntawm inhibiting cov enzyme protease uas HIV xav tau rov ua dua, yog li txo cov kab mob hauv lub cev. Nws inhibits qhov kev ua ntawm protease enzyme, uas yog qhov tseem ceeb rau kev loj hlob ntawm cov kab mob sib kis. Los ntawm kev tiv thaiv cov txheej txheem no, cov tshuaj pab txhawm rau txhawm rau txhawm rau txhawm rau kis tus kabmob, yog li tswj kev kis tus kabmob.

Shaanxi Medibridge Biotech Co., Ltd. tsom rau kev muab cov khoom siv tshuaj raw khoom thiab kev tshawb fawb- siv cov khoom sib txuas. Peb txhawb cov neeg siv khoom nrog kev ruaj khov zoo, kev sib txuas lus meej meej, kev xaiv ntim tau yooj yim, thiab cov ntaub ntawv - cuam tshuam txog kev txhawb nqa rau theem sib txawv.

Competitive Binding thiab Protease Cleavage Inhibition

Hloov pauv-State Mimicry: Cov pab pawg hauv nruab nrab hydroxyl (-OH) ntawm Atazanavir ua raws li kev hloov pauv ntawm lub xeev thaum lub sij hawm peptide daim ntawv cog lus cleavage, ua kom muaj kev sib tw nruj rau ob lub catalytic aspartic acid residues (Asp25 / Asp25') hauv HIV-1 protease site homodimer

Blockade of Gag / Gag-Pol Processing: Los ntawm kev xaiv inhibiting viral polyprotein processing, Atazanavir tiv thaiv capsid core condensation thiab virion maturation, ua tsis tau - kis, morphologically tsis paub qab hau kab mob.

Lub Koom Haum Metabolic Enzymes thiab Transporter Interactions

UGT1A1 Enzyme Inhibition: Atazanavir yog ib qho muaj zog inhibitor ntawm tib neeg uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). Nws thaiv cov glucuronidation ntawm unconjugated bilirubin, ua tus thawj molecular tsav tsheb rau hyperbilirubinemia hauv kev soj ntsuam thiab preclinical kev nyab xeeb kev tshawb fawb.

CYP3A4 thiab P-gp Substrate/Inhibitor: Nws ua haujlwm raws li ob qho tib si substrate thiab kev sib tw inhibitor ntawm cytochrome P450 3A4 (CYP3A4) thiab P-glycoprotein (P-gp" / ABCB1), ua rau nws yog ib qho tseem ceeb siv compound rau kev tshawb xyuas mbone pharomerane thauj kinetics.

Atazanavir solubility txo qis thaum pH nce. Yog li ntawd, gastric acidity yog ib qho tseem ceeb hauv kev nqus ntawm qhov ncauj, thiab cov kua qaub-txo cov tshuaj tuaj yeem txo qhov raug atazanavir. Qhov kev cia siab pH no yuav tsum raug txiav txim siab thoob plaws hauv kev xaiv API, tsim kev tsim kho, thiab kev ntsuam xyuas ntawm kev sib tshuam tshuaj.

Ib qho kev solubility tshwm sim hauv cov dej ntshiab tsis txaus los qhia nws tus cwj pwm tsim. Kev ntsuas muaj txiaj ntsig ntau suav nrog kev solubility thiab kev sib cais nyob rau hauv cov xwm txheej pH, qhov loj me, cov khoom hauv lub xeev, thiab kev ruaj ntseg nrog cov khoom siv ntxiv. Ib qho kev hloov hauv daim ntawv ntsev lossis qhov loj me tuaj yeem txhim kho kev sib cais raws li kev sim xaiv, tab sis nws cov txiaj ntsig ntawm cov khoom tiav yuav tsum raug txheeb xyuas.

Atazanavir zoo sib xws nrog CYP3A- cov metabolism hauv nruab nrab thiab inhibits UGT1A1. Cov kev tshawb fawb kev sib tham yuav tsum xav txog ob qho kev qhia: ib co-cov tshuaj tswj hwm yuav hloov pauv qhov kis ntawm atazanavir, thaum atazanavir lossis nws cov tshuaj tuaj yeem hloov pauv mus rau lwm cov tshuaj. Acid-cov tshuaj txo qis, CYP3A- cov tshuaj muaj feem xyuam, thiab lwm yam tshuaj tiv thaiv kab mob yog pab pawg tseem ceeb los ntsuas.

Kev hloov pauv hauv HIV-1 protease gene tuaj yeem txo qis kev nkag mus rau atazanavir. Kev ntsuas kev tiv thaiv yuav tsum xav txog ua ntej raug rau cov tshuaj tiv thaiv protease, tus kab mob protease genotype, phenotypic susceptibility thaum muaj, thiab kev ua haujlwm ntawm lwm cov tshuaj hauv kev tswj hwm. Ib qho kev hloov pauv ib leeg yuav tsum tsis txhob raug kho raws li qhov ua tiav ntawm qhov sib txawv ntawm qhov sib txawv: kev sib txuas ntawm kev hloov pauv thiab keeb kwm kev kho mob cuam tshuam rau kev txhais lus.